Skip to main content

Table 4 Estimated hazard ratio of ovarian cancer prior to the era of targeted therapy

From: Changes in ovarian cancer survival during the 20 years before the era of targeted therapy

 

N

No. of deaths

Adjusted HRb

95% CI

p-value

Age (years)

  < 40

3849

988

ref.

ref.

 40–59

12,169

4992

1.71

(1.60–1.84)

<.0001

  > 59

6862

4328

3.00

(2.79–3.22)

<.0001

SEER Stage

 Early stagea

6429

1113

ref.

ref.

 Distant stage

6795

3777

3.23

(3.02–3.46)

<.0001

Year of diagnosis

 1995–1999

3740

2230

ref.

ref.

 2000–2004

4863

2671

0.89

(0.84–0.95)

0.000

 2005–2009

6317

3227

0.94

(0.85–1.03)

0.185

 2010–2014

7960

2180

0.73

(0.65–0.81)

<.0001

Primary treatment

 With surgery

19,776

8122

ref.

ref.

 Without surgery

1772

1233

1.49

(1.39–1.58)

<.0001

Histology

 Serous carcinoma

10,837

5325

ref.

ref.

 Mucinous carcinoma

4005

1226

0.71

(0.67–0.76)

<.0001

 Endometrioid carcinoma

2191

670

0.69

(0.63–0.75)

<.0001

 Clear cell carcinoma

1923

507

0.80

(0.73–0.88)

<.0001

 Others

3924

2580

1.49

(1.42–1.57)

<.0001

  1. aEarly stage: local + regional, HR, hazard ratio; ref., reference; CI, confidence interval; SEER, Surveillance, Epidemiology, and End Results
  2. badjusted for Age, SEER stage, Year of Diagnosis, Primary treatment and Histology